The lowering of the price target from $95 to $78 by Scotiabank suggests a less optimistic view on Biomarin's future performance, which could lead to a negative short-term impact on the stock price. The maintained Sector Perform rating indicates that the stock is expected to perform in line with the sector, but the reduced price target reflects potential challenges or lower growth expectations.